Here are 1-2 brief analogies for Amylyx Pharmaceuticals (AMLX):

• Vertex Pharmaceuticals for rare neurodegenerative diseases.
• A smaller Biogen focused on ALS and other neurodegenerative conditions.

• AMX0035: A dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid, developed for treating ALS and other neurodegenerative diseases.

Amylyx Pharmaceuticals (AMLX), as a biopharmaceutical company developing and selling prescription therapeutics, primarily sells its products to other companies rather than directly to individual patients. Their major customers are typically pharmaceutical wholesalers and distributors who manage the distribution of drugs to pharmacies, hospitals, and other healthcare providers.

Based on the standard pharmaceutical distribution model in the United States, Amylyx Pharmaceuticals' major customers would include:

• McKesson Corporation (NYSE: MCK)
• AmerisourceBergen Corporation (NYSE: ABC)
• Cardinal Health, Inc. (NYSE: CAH)

These companies are the largest pharmaceutical wholesalers in the U.S. and are responsible for distributing a significant majority of prescription medications to healthcare providers and pharmacies nationwide.

• Thermo Fisher Scientific Inc. (TMO)
• TCI Co., Ltd. (TYO: 4026)
• Dipharma Francis S.r.l.

Joshua Cohen, Co-Chief Executive Officer & Co-Founder

Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and has served as its Co-Chief Executive Officer since 2014. He oversaw the company's growth through its IPO, FDA and Health Canada approvals, and product launch, and co-invented AMX0035. He holds a B.S. in Biomedical Engineering from Brown University, where he founded the Brown Biotechnology Investment Group and published research.

Justin Klee, Co-Chief Executive Officer & Co-Founder

Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and serves as its Co-Chief Executive Officer. He, alongside Josh Cohen, guided Amylyx from a concept to a global, commercial-stage company, overseeing regulatory approvals for AMX0035 in Canada and the U.S. Klee co-invented AMX0035. He earned a Bachelor of Science in neuroscience from Brown University and conducted research in neural systems at Brown and in neurophysiology and Alzheimer's disease at Harvard Medical School. He is a published author in several high-impact journals.

James M. Frates, Chief Financial Officer

James M. Frates joined Amylyx Pharmaceuticals as Chief Financial Officer in January 2021. Prior to Amylyx, he was the CFO at Alkermes from July 1998 to January 2021, where he helped grow the company from a clinical-stage entity to an international commercial and development enterprise. Frates managed Alkermes through numerous acquisitions and financings in the debt, equity, and private markets. His career also includes experience as an investment banker at Robertson, Stephens & Company, focusing on Biotechnology Investment Banking, and at Morgan Stanley. He holds a Bachelor's degree from Harvard University and an MBA from Harvard Business School.

Linda A. Arsenault, Chief Human Resources Officer

Linda A. Arsenault serves as the Chief Human Resources Officer at Amylyx Pharmaceuticals.

Gina M. Mazzariello, Chief Legal Officer & General Counsel

Gina M. Mazzariello holds the position of Chief Legal Officer & General Counsel at Amylyx Pharmaceuticals.

The key risks to Amylyx Pharmaceuticals (AMLX) primarily stem from the failure and withdrawal of its main product and subsequent reliance on its early-stage pipeline.

1. Failure of RELYVRIO/ALBRIOZA (AMX0035) and Loss of Product Revenue: The most significant risk to Amylyx Pharmaceuticals is the voluntary withdrawal of its flagship drug, RELYVRIO (known as ALBRIOZA in Canada), from the market in the U.S. and Canada, effective April 4, 2024. This decision was made after the Phase 3 PHOENIX trial for AMX0035 in Amyotrophic Lateral Sclerosis (ALS) failed to meet its primary and secondary endpoints, indicating a lack of efficacy. This drug was the company's sole source of revenue, generating $381 million in 2023. The withdrawal led to a substantial reduction of approximately 70% in the company's workforce and a restructuring to focus on its remaining pipeline.
2. High Dependence on Pipeline and Clinical Trial Risks: Following the withdrawal of RELYVRIO for ALS, Amylyx's future now heavily relies on the success of its remaining pipeline candidates, particularly AMX0035 in Wolfram syndrome and AMX0114 in ALS. The company previously also discontinued the AMX0035 program for Progressive Supranuclear Palsy (PSP) after its Phase 2b ORION trial failed to meet its primary endpoint in August 2025. Additionally, the European Medicines Agency (EMA) repeatedly rejected AMX0035 for approval in Europe due to concerns about its effectiveness, further highlighting the significant regulatory hurdles and inherent risks associated with drug development.
3. Financial Viability and Potential for Dilution: With the cessation of RELYVRIO sales, Amylyx has no current product revenue. While the company has implemented a restructuring plan to extend its cash runway into 2026, its long-term financial viability is now entirely dependent on the successful development and commercialization of its pipeline. This situation creates a risk of needing to raise additional capital, potentially through equity or hybrid offerings, which could lead to significant shareholder dilution. The company also faces ongoing legal challenges, including a class-action lawsuit alleging misleading statements related to RELYVRIO's commercial prospects, which could result in financial penalties and reputational harm.

The primary clear emerging threat for Amylyx Pharmaceuticals is the failure of its global Phase 3 PHOENIX trial for AMX0035 (marketed as RELYVRIO in the U.S. and ALBRIOZA in Canada) in amyotrophic lateral sclerosis (ALS). In March 2024, Amylyx announced that the PHOENIX trial did not meet its primary endpoint, failing to demonstrate a statistically significant benefit on functional outcomes or survival. This development significantly undermines the clinical validation of their key approved product, raising substantial questions about its continued regulatory approval, physician prescribing trends, and long-term commercial viability for its primary indication.

Amylyx Pharmaceuticals (AMLX) focuses on developing therapeutics for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Wolfram syndrome, and Alzheimer's disease. The addressable markets for their main products and services are substantial both globally and in the United States.

Amyotrophic Lateral Sclerosis (ALS)

• The global market for ALS treatments was valued at approximately USD 713.3 million in 2023 and is projected to grow to USD 987.6 million by 2030, with a compound annual growth rate (CAGR) of 5.8% from 2024 to 2030. Other estimates place the global market at USD 726.62 million in 2024, expected to reach USD 1,041.27 million by 2032, at a CAGR of 4.6% (2025-2032). Another report valued the global ALS treatment market size at USD 662.3 million in 2022, projected to reach USD 1,038.94 million by 2032, growing at a CAGR of 4.6% from 2023 to 2032.
• In the United States, the ALS treatment market was estimated at USD 206.78 million in 2023, with a projected CAGR of 4.5% during the forecast period. Another source indicates the U.S. market for ALS was USD 800 million in 2024. North America, where the U.S. holds a major share, is expected to reach USD 515.6 million by 2032, growing at a 5.2% CAGR.

Wolfram Syndrome

• The global Wolfram syndrome treatment market is estimated at USD 14.78 billion by 2025 and is projected to grow at a CAGR of 7.83% through 2033. Another projection indicates the market size to grow from USD 1885.52 billion in 2025 to USD 3097.40 billion by 2034, at a CAGR of 5.67% during the forecast period (2026-2034).
• Wolfram syndrome is a rare condition, affecting approximately 15,000 to 30,000 patients globally, with an estimated 1,000 to 2,000 people affected in the U.S. in 2019. While a specific U.S. market size was not explicitly detailed, North America is anticipated to account for a notable share of the global market.

Alzheimer's Disease

• The global Alzheimer's therapeutics market size was estimated at USD 4.05 billion in 2022 and is anticipated to reach USD 15.19 billion by 2030, growing at a CAGR of 19.99% from 2023 to 2030. Another report values the global market at USD 6.49 billion in 2025, predicted to reach approximately USD 33.62 billion by 2034, growing at a CAGR of 20.06% from 2025 to 2034. The global Alzheimer's disease therapeutics market is expected to reach approximately US$ 31.04 billion by 2034, from US$ 5.36 billion in 2024, growing at a CAGR of 19.2% during the forecast period 2025 to 2034.
• In the United States, the Alzheimer's therapeutics market is projected to reach US$ 6,441.3 million by 2030, with a CAGR of 19.1% from 2023 to 2030. The U.S. Alzheimer's drugs market size was USD 1.62 billion in 2022. North America accounted for approximately 54% of the total Alzheimer's disease market in the 7MM (US, EU4, UK, Japan) in 2023.

Amylyx Pharmaceuticals (AMLX) is poised for potential future revenue growth over the next 2-3 years, primarily driven by its pipeline advancements following the discontinuation of its ALS treatment, Relyvrio/Albrioza. The key drivers are centered around new product launches and the progression of its investigational therapies.

1. Commercial Launch of Avexitide for Post-Bariatric Hypoglycemia (PBH): This is anticipated to be a significant revenue driver for Amylyx. The pivotal Phase 3 LUCIDITY trial for avexitide in PBH has completed recruitment, with topline data expected in the third quarter of 2026. Should the trial be successful and regulatory approval be granted, a commercial launch is projected for 2027. Avexitide has also received FDA Breakthrough Therapy Designation for PBH, highlighting the unmet medical need in this area. Analysts have forecasted potential revenue from avexitide, with estimates of $45.6 million in two years and $114.4 million in three years, based on an estimated annual revenue of $110,000 per patient.
2. Advancement and Potential Future Approval of AMX0035 for Wolfram Syndrome: While AMX0035 (Relyvrio/Albrioza) was discontinued for ALS, Amylyx continues to develop it for other neurodegenerative diseases, including Wolfram syndrome. Positive 48-week data from the Phase 2 HELIOS clinical trial demonstrated sustained stabilization or improvement in multiple outcomes for Wolfram syndrome. Amylyx plans to initiate a pivotal Phase 3 trial for this indication, pending alignment with the FDA, which could lead to a new product offering within the 2-3 year timeframe if development progresses efficiently.
3. Progress of AMX0114 in ALS Clinical Trials: Amylyx is advancing AMX0114, an investigational antisense oligonucleotide (ASO) targeting calpain-2, for the potential treatment of amyotrophic lateral sclerosis (ALS). The Phase 1 LUMINA clinical trial has completed enrollment for Cohort 1 and is enrolling Cohort 2, with early safety data indicating it was generally well-tolerated. Biomarker data from this trial are expected in the first half of 2026. With FDA Fast Track Designation for ALS, positive clinical progression and data readouts could accelerate its development and signal future revenue potential for the company.
4. Development of AMX0318 for PBH and Other Rare Diseases: Amylyx announced AMX0318 as a development candidate in collaboration with Gubra in December 2024. This long-acting GLP-1 receptor antagonist is being developed for post-bariatric hypoglycemia and other rare diseases. An Investigational New Drug (IND) application for AMX0318 is expected in 2027, marking a step towards expanding the company's pipeline and offering further opportunities for revenue generation in the longer term.

Share Issuance

• In January 2022, Amylyx Pharmaceuticals completed its initial public offering, raising net proceeds of $196.9 million at $19 per share.
• In October 2022, Amylyx closed an upsized underwritten public offering of its common stock, with gross proceeds of $246.3 million.
• In 2025, the company conducted two secondary offerings. One in January 2025, which expected to raise approximately $60.0 million in gross proceeds from the offering of 17,142,857 shares at $3.50 per share, with net proceeds primarily for commercialization, pipeline programs, and working capital. A second offering in September 2025, priced at $10.00 per share for 17,500,000 shares, was expected to yield gross proceeds of $175.0 million, earmarked for Avexitide commercial readiness, research and development, and general corporate purposes.

Inbound Investments

• In the third quarter of 2025, Saturn V Capital Management significantly increased its stake in Amylyx Pharmaceuticals by 1.3 million shares, bringing its position value to $62.6 million.
• During Q3 2025, institutional investors made substantial additions to their portfolios, including FMR LLC adding 8,331,188 shares (estimated $113,220,844), COMMODORE CAPITAL LP adding 4,075,478 shares (estimated $55,385,746), and FIRST LIGHT ASSET MANAGEMENT, LLC adding 3,355,882 shares (estimated $45,606,436).